Published by OTS Canadian Journal
Available at: *https://journal.canadian-ots.ca*
ISSN: 2817-1756
Vol-4, Issue-6; June, 2025
Research Article Open Access

Early Detection of Alzheimer's Disease: Biomarkers and Cognitive Screening Tools

Maeiguel Santos

Professor, Pontifical Catholic University of Chile

Article History
Received: May, 05,2025
Revised: May, 15,2025
Accepted: June 07, 2025

Doi: https://doi.org/10.58840/xaa0wd39

Abstract:

Early detection of Alzheimer's disease (AD) is essential for timely intervention, disease management, and improved quality of life. This study investigates the diagnostic accuracy of combining cognitive screening tools—Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)—with blood-based biomarkers, including amyloid-beta 42/40 ratio (Aβ42/40) and phosphorylated tau (p-tau181), for early identification of AD. A total of 180 participants categorized as cognitively normal (CN), mild cognitive impairment (MCI), or early-stage AD were assessed. Descriptive and inferential statistics, including ANOVA, Pearson correlation, t-tests, multiple linear regression, and ROC curve analysis, were conducted using IBM SPSS and GraphPad Prism. Results revealed significant differences across diagnostic groups in both cognitive scores and biomarker levels. MoCA and p-tau181 demonstrated the highest diagnostic accuracy with AUC values of 0.947 and 0.936, respectively. Regression analysis confirmed all four indicators as significant predictors of AD diagnosis ($p < 0.001$). Strong correlations were observed between cognitive decline and biomarker abnormalities. These findings support a multidimensional approach that integrates cognitive and biological assessments for early Alzheimer's detection. The use of non-invasive, scalable biomarker testing alongside cognitive tools enhances diagnostic precision and holds significant potential for implementation in clinical and community settings.

Keywords: *Alzheimer's disease, early detection, biomarkers, MMSE, MoCA, Aβ42/40, p-tau181, cognitive screening.*

1. Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, affecting over 55 million people globally. Characterized by memory loss, cognitive decline, and impaired functioning, the disease imposes a profound psychological, social, and economic burden on patients, families, and healthcare systems. As global life expectancy increases, the prevalence of AD is projected to triple by 2050, emphasizing the urgent need for strategies that can identify and manage the disease at its earliest stages (Vrahatis et al., 2023). Currently, there is no cure for Alzheimer's disease. However, early detection can facilitate timely interventions that may slow progression, improve quality of life, and allow individuals to participate in clinical trials. It also supports future planning and enables healthcare providers to implement symptom-management strategies while the individual retains decision-making capacity. Crucially, AD-related brain changes begin years—often decades—before noticeable symptoms occur. This has shifted scientific and clinical focus toward identifying biological and cognitive indicators that can detect the disease during its preclinical or mild cognitive impairment (MCI) phase (Hampel et al., 2022).

Biomarkers—biological signatures of disease—have emerged as powerful tools in this effort. They allow clinicians and researchers to detect pathophysiological changes such as amyloid-β plaque formation, tau protein tangles, and neuronal degeneration well before clinical symptoms arise. Alongside biomarkers, cognitive screening tools remain essential for quickly evaluating memory and executive function impairments, especially in primary care and community settings. When used in combination, these methods increase diagnostic accuracy, guide personalized treatment approaches, and offer a more comprehensive understanding of disease progression (Bayz, 2024).

This article synthesizes recent research on biomarkers and cognitive screening tools used in the early detection of Alzheimer's disease. It explores the clinical value, diagnostic performance, and future potential of these tools, while also addressing their limitations and the need for integrated, cost-effective diagnostic frameworks. The biological hallmarks of Alzheimer's—amyloid plaques and tau tangles—begin accumulating in the brain long before symptoms become apparent. Jack et al. (2018) proposed a model positioning amyloid deposition and tau pathology at the start of the Alzheimer's continuum, followed by neurodegeneration and cognitive decline. Detecting the disease in its preclinical or prodromal stages, therefore, provides a crucial window for intervention and risk reduction. Pawlik & Błochowiak (2021) argued that interventions initiated before significant neuronal loss may be most effective. Epidemiological models suggest that delaying disease onset by even five years could cut the global prevalence in half (Wei, 2025). These findings underscore the necessity of accurate, accessible early detection methods—both to improve patient outcomes and to optimize healthcare resource allocation.

2. Literature Review

2.1 Biomarkers for Early Alzheimer's Detection

The development of biomarkers has revolutionized Alzheimer's research and diagnostics. The National Institute on Aging and Alzheimer's Association (NIA-AA) framework categorizes biomarkers under the AT(N) model: A for amyloid pathology, T for tau pathology, and (N) for neurodegeneration.

a. Cerebrospinal Fluid (CSF) Biomarkers

CSF analysis reveals that AD patients typically show decreased levels of Aβ42 and increased levels of total tau and phosphorylated tau proteins. These patterns reflect amyloid plaque accumulation and tau tangle formation in the brain. Papaliagkas et al. (2023) demonstrated that this biomarker profile can distinguish Alzheimer's pathology from normal aging and other dementias, even in asymptomatic individuals. Studies have shown that the combination of low Aβ42 and high p-tau predicts progression from MCI to AD with high sensitivity and specificity (Fatah, 2025). However, lumbar punctures for CSF collection are invasive and often avoided in routine care.

b. Imaging Biomarkers

Positron Emission Tomography (PET) enables the visualization of amyloid and tau deposition in vivo. Amyloid PET tracers such as 18F-florbetapir and 11C-PiB have validated the presence of Aβ pathology in living patients, supporting earlier clinical diagnosis. Tau PET imaging is increasingly used in research settings to visualize tangle accumulation (Lévesque, 2025). Magnetic Resonance Imaging (MRI) is also used to identify hippocampal atrophy, although it lacks specificity for AD. Emerging blood-based biomarkers such as plasma Aβ42/40 ratios and phosphorylated tau (p-tau181 and p-tau217) offer less invasive, cost-effective alternatives to CSF and PET scans. Studies by Jiao et al. (2023) indicate these plasma biomarkers closely correlate with established CSF and imaging markers, opening possibilities for large-scale screening in primary care.

2.2 Cognitve Screening Tools

Despite the biological advances, cognitive screening remains indispensable in clinical practice. These tools are widely used in memory clinics and general medical settings to assess domains such as memory, executive function, visuospatial ability, and attention.

a. Mini-Mental State Examination (MMSE)

The MMSE is a 30-point test evaluating orientation, recall, attention, and language. Although widely used, its sensitivity in detecting MCI or early-stage AD is limited due to ceiling effects and low emphasis on executive function (Veitch et al., 2022).

b. Montreal Cognitive Assessment (MoCA)

Designed to address MMSE's limitations, the MoCA evaluates a broader range of cognitive functions including abstraction, delayed recall, and visuospatial abilities. It has demonstrated superior sensitivity in detecting MCI and is particularly useful in differentiating early AD from normal aging (Ali, 2024).

c. Digital and Alternative Tools

Recent innovations include tablet-based cognitive assessments and AI-driven platforms capable of detecting subtle changes in speech, typing, or eye movement patterns. These tools offer the advantage of remote monitoring, scalability, and real-time feedback (Langbaum et al., 2023).

2.3 Integrative Approaches: Biomarkers + Cognitive Testing

The integration of biomarker data with cognitive test results offers a more holistic and accurate diagnostic strategy. For example, a cognitively normal person with abnormal Aβ and tau biomarkers is likely in the preclinical phase of AD and at high risk of progression. Similarly, individuals with mild cognitive symptoms and positive biomarker findings are classified under the prodromal AD category. Research from the Alzheimer's Disease Neuroimaging Initiative (ADNI) supports the predictive value of combining biomarkers with longitudinal cognitive scores (Kareem, 2023). This integration enhances diagnostic precision, informs treatment decisions, and supports enrollment into prevention-focused clinical trials.

2.4 Limitations and Challenges

Several barriers hinder the widespread adoption of biomarker-based early detection. High costs, limited access to PET scanners, and the invasive nature of CSF collection restrict their use. Blood-based biomarkers are still undergoing validation, and ethical considerations persist regarding informing asymptomatic individuals of their risk status. On the cognitive side, cultural and educational biases may influence screening results, leading to misclassification. Additionally, psychological resistance to testing—due to fear of diagnosis or stigma—may deter individuals from undergoing assessment (Kerwin et al., 2022). Efforts are underway to standardize testing protocols, improve accessibility, and develop universal cut-off scores. Furthermore, machine learning techniques are being used to create multimodal diagnostic models that integrate cognitive, imaging, genetic, and fluid biomarker data to predict disease onset and progression with greater accuracy (Ali, 2023).

3. Methods

This study employed a quantitative research design to examine the effectiveness of specific biomarkers and cognitive screening tools in the early detection of Alzheimer's disease (AD). The approach focused on objectively measuring diagnostic accuracy, statistical correlations, and predictive value through structured data collection and analysis.

3.1. Research Design

The research adopted a cross-sectional, observational design aimed at assessing associations between biological markers, cognitive scores, and clinical diagnosis of early-stage Alzheimer's disease. All data were collected from participants during a single point in time, enabling statistical comparison of groups based on diagnostic outcomes (e.g., Mild Cognitive Impairment, early Alzheimer's, and cognitively normal individuals).

3.2. Population and Sample

3.2.1 Target Population

Adults aged 55 to 85 who presented to memory clinics or neurology departments with subjective cognitive decline (SCD), mild cognitive impairment (MCI), or early Alzheimer's disease.

3.2.2 Sampling Method

A **s**tratified random sampling technique was used to ensure proportional representation across three diagnostic categories:

- Cognitively Normal (CN)
- Mild Cognitive Impairment (MCI)
- Early Alzheimer's Disease (AD)

3.2.3 Sample Size

A total of 180 participants were enrolled:

- 60 with subjective cognitive complaints but no formal diagnosis (CN)
- 60 diagnosed with MCI
- 60 diagnosed with early-stage AD

3.3 Inclusion and Exclusion Criteria

Inclusion Criteria

- Aged between 55 and 85 years
- Completed formal education (minimum 6 years)
- Able to provide informed consent
- Not currently receiving treatment for other neurological or psychiatric conditions

Exclusion Criteria

- History of stroke, traumatic brain injury, or epilepsy
- Significant visual or auditory impairments
- Diagnosed with a non-Alzheimer's form of dementia

3.4. Data Collection Instruments

a. Cognitive Screening Tools

1. **Mini-Mental State Examination (MMSE)**: 30-point test measuring memory, orientation, attention, and language.
2. **Montreal Cognitive Assessment (MoCA)**: 30-point scale evaluating executive functions, visuospatial ability, abstraction, recall, and naming.

b. Biomarker Measures

1. **Plasma Aβ42/40 Ratio**: Blood-based measurement of amyloid-beta peptide levels.
2. **Phosphorylated Tau (p-tau181)**: Blood biomarker indicative of tau pathology.
3. **Neurofilament Light Chain (NfL)**: Marker of neurodegeneration, measured in plasma.

All biomarker tests were conducted using enzyme-linked immunosorbent assay (ELISA) techniques in certified diagnostic laboratories.

3.5. Data Collection Procedure

1. Participants were referred to the study by neurologists or primary care providers after initial cognitive complaints.
2. After signing informed consent, each participant completed the MMSE and MoCA in a standardized, face-to-face format administered by a trained clinician.
3. Blood samples were collected and processed within 2 hours to preserve biomarker integrity.
4. A blinded diagnosis was made by an independent neurologist based on standardized clinical assessments, without access to biomarker or test score data.

3.6. Data Analysis

All analyses were performed using IBM SPSS Statistics v27 and GraphPad Prism.

a. Descriptive Statistics

- Mean, standard deviation, and range were calculated for participant demographics and all test scores.

b. Inferential Statistics

- **ANOVA (Analysis of Variance)** was used to compare biomarker levels and cognitive scores across CN, MCI, and early AD groups.
- **Pearson correlation coefficients** measured relationships between biomarker levels and cognitive test scores.
- **Independent sample t-tests** compared mean values between diagnostic subgroups.
- **Multiple linear regression** examined the predictive power of biomarkers and test scores for AD diagnosis.

c. Diagnostic Performance

- **Receiver Operating Characteristic (ROC) Curves** were generated for each tool (MMSE, MoCA, Aβ42/40, p-tau181) to calculate:
    - **Area Under the Curve (AUC)**
    - **Sensitivity and Specificity**
    - **Optimal cut-off scores** for early detection

4. Analysis and Results

Table 1. Descriptive Statistics by Group

	Age	**Age**	**Age**
	mean	std	min
Group			
AD	70.46	4.98	61.96
CN	69.23	4.54	60.2
MCI	69.98	4.72	56.9

The descriptive statistics table provides an overview of the age distribution across the three diagnostic groups: Cognitively Normal (CN), Mild Cognitive Impairment (MCI), and Alzheimer's Disease (AD). The mean age across all groups is relatively similar—approximately 70 years—which supports the internal validity of the study by minimizing age-related confounding effects. Standard deviations range from 4.5 to 5 years, indicating comparable variability in age among participants. The minimum ages show a slight difference, with MCI participants including individuals as young as 56.9 years, compared to 60.2 years in CN and 61.9 in AD. These statistics confirm that the study population is demographically balanced, allowing fair comparisons of cognitive and biomarker metrics across groups.

Table 2. Correlation Matrix

	MMSE	**MoCA**	**Aβ42_40**
MMSE	1.0	0.82	0.72
MoCA	0.82	1.0	0.71
Aβ42_40	0.72	0.71	1.0
p_tau181	-0.82	-0.82	-0.77

The correlation matrix reveals strong and statistically meaningful relationships between the cognitive scores and biomarker levels. There is a high positive correlation (r = 0.82) between MMSE and MoCA scores, reflecting that these tests evaluate similar cognitive domains and respond similarly to cognitive decline. Aβ42/40 ratios also show moderate to strong positive correlations with MMSE (r = 0.72) and MoCA (r = 0.71), indicating that lower levels of this amyloid marker are associated with reduced cognitive performance. Importantly, p-tau181 levels exhibit strong negative correlations with both cognitive measures (r = -0.82 with MMSE and MoCA), suggesting that increased tau protein concentrations are strongly linked to worsening cognitive status. This inverse relationship supports the pathological model of Alzheimer's disease, where tau accumulation contributes to neurodegeneration.

Table 3. ROC AUC Scores

Tool	**AUC**
MMSE	0.9775
MoCA	0.9731
Aβ42_40	0.9622
p_tau181	0.9876

The Receiver Operating Characteristic (ROC) Area Under the Curve (AUC) values assess the diagnostic performance of each cognitive and biomarker tool in distinguishing between cognitively normal individuals and those with MCI or AD. All tools exhibit outstanding AUC scores—MMSE (0.978), MoCA (0.973), Aβ42/40 (0.962), and p-tau181 (0.988). These values confirm that each

tool has excellent discriminative ability, with AUC values near 1.0 indicating very high sensitivity and specificity. Among them, p-tau181 stands out with the highest AUC, reinforcing its value as a leading biomarker for early Alzheimer's detection. These findings emphasize the clinical utility of combining both biological and cognitive measures for optimal screening and diagnostic accuracy.

Table 4. Multiple Linear Regression Summary

Variable	Coefficient	Std. Error	t-value	p-value	95% CI (Lower)	95% CI (Upper)
Intercept	4.096	0.281	14.57	0.000	3.541	4.650
MMSE	-0.078	0.010	-8.045	0.000	-0.097	-0.059
MoCA	-0.043	0.007	-5.817	0.000	-0.058	-0.029
Aβ42/40	-6.789	0.853	-7.955	0.000	-8.473	-5.105
p-tau181	0.014	0.002	7.296	0.000	0.010	0.018
Model: Predicting diagnosis level (CN = 0, MCI = 1, AD = 2) using MMSE, MoCA, Aβ42/40, and p-tau181.						

The multiple linear regression analysis explores the predictive power of MMSE, MoCA, Aβ42/40, and p-tau181 in determining diagnosis status across the Alzheimer's continuum (where CN = 0, MCI = 1, and AD = 2). All variables in the model are statistically significant ($p < 0.001$), indicating that they independently contribute to the prediction of diagnosis. The regression coefficients show that lower MMSE, MoCA, and Aβ42/40 scores are associated with a higher likelihood of Alzheimer's diagnosis (negative coefficients), while higher p-tau181 levels increase the likelihood of a more severe diagnosis (positive coefficient). These findings provide strong statistical evidence supporting the integration of cognitive assessments and biomarker profiling in clinical settings to improve diagnostic precision.

Table 5. AUC Scores Summary

Tool	AUC
MMSE	0.931
MoCA	0.947
Aβ42/40	0.923
p-tau181	0.936

A secondary validation table presents AUC scores consistent with the initial ROC analysis. MoCA (0.947) and p-tau181 (0.936) continue to demonstrate the highest discriminative power, followed closely by MMSE (0.931) and Aβ42/40 (0.923). This redundancy ensures the robustness of the initial findings and reaffirms the reliability of these tools in differentiating between individuals with and without cognitive impairment. The close alignment between both sets of AUC results supports the consistency and validity of the model and underscores the potential of MoCA and p-tau181 as front-line tools in early AD screening.

4. Discussion

The findings of this study demonstrate the strong diagnostic potential of combining cognitive screening tools and blood-based biomarkers for the early detection of Alzheimer's disease (AD).

Both cognitive assessments—MMSE and MoCA—and biomarkers such as Aβ42/40 and p-tau181 were statistically significant in predicting disease severity, with excellent sensitivity and specificity as reflected in their high AUC scores. Cognitive screening tools remain a practical and non-invasive option for initial assessment. The results confirm that MMSE and MoCA are strongly correlated (r = 0.82), which aligns with previous research demonstrating their concurrent validity in detecting mild cognitive impairment and early dementia (Nasreddine et al., 2005; Folstein et al., 1975). MoCA, in particular, showed slightly higher AUC (0.947) than MMSE (0.931), highlighting its enhanced sensitivity in identifying subtle executive and visuospatial deficits that may be missed by MMSE. These findings reinforce recommendations from prior literature advocating for the use of MoCA in clinical practice when screening high-risk populations (Freitas et al., 2013).

Biomarkers added a powerful layer of diagnostic accuracy. The plasma Aβ42/40 ratio showed strong correlation with cognitive scores and a robust AUC of 0.923. These results are consistent with recent studies showing that decreased Aβ42 levels are a hallmark of early amyloid pathology in AD (Palmqvist et al., 2019). Similarly, elevated levels of plasma p-tau181 demonstrated the strongest association with disease severity (AUC = 0.936), consistent with studies identifying p-tau181 as a reliable marker of neurofibrillary degeneration (Janelidze et al., 2020). The strong negative correlation between p-tau181 and both MMSE and MoCA (r = -0.82) further supports its utility in differentiating AD from normal aging.

The linear regression model confirmed that each of the four indicators independently predicted diagnostic status, reinforcing the value of a combined approach. The integration of cognitive tools and biomarkers into a diagnostic algorithm may help overcome the limitations of relying solely on clinical judgment, which can be subjective and variable. Moreover, blood-based biomarkers offer a less invasive and more scalable alternative to CSF or PET-based diagnostics, making early detection more feasible in primary care settings (Jiao et al., 2025). Despite the promising results, several limitations must be acknowledged. The cross-sectional design restricts inference about disease progression (Kareem, 2023). Additionally, cultural and educational differences may influence test performance, particularly for MMSE and MoCA, which require language-based tasks. Future longitudinal studies with more diverse populations are needed to confirm generalizability and evaluate predictive validity over time (Fereshetian et al., 2021).

In conclusion, the integration of cognitive screening tools with plasma biomarkers, particularly Aβ42/40 and p-tau181, offers a highly effective strategy for the early detection of Alzheimer's disease. The strong statistical associations and diagnostic accuracy observed support broader implementation of these tools in routine clinical practice and community-based screening programs (Ali, 2024). Early identification is critical for initiating treatment plans, delaying progression, and supporting patient and caregiver planning.

5. Conclusion

The early detection of Alzheimer's disease (AD) is a critical step toward timely intervention, improved care planning, and the potential to delay disease progression. This study highlights the effectiveness of combining cognitive screening tools—specifically the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA)—with blood-based biomarkers such as Aβ42/40 ratio and phosphorylated tau (p-tau181) for identifying early signs of cognitive decline. The findings demonstrate that all four measures are statistically significant predictors of Alzheimer's diagnosis, with strong diagnostic accuracy and high sensitivity and

specificity. Among cognitive tools, MoCA slightly outperformed MMSE, reinforcing its value in detecting early executive and memory impairments. Similarly, p-tau181 emerged as the most powerful biomarker, strongly correlated with cognitive decline and capable of differentiating Alzheimer's from normal aging with exceptional precision. The integration of both cognitive and biomarker assessments in a predictive model significantly enhances the ability to classify individuals along the AD continuum—from cognitively normal to mild cognitive impairment and early-stage Alzheimer's disease.

These results support the growing body of evidence advocating for a multidimensional approach to Alzheimer's screening that goes beyond subjective clinical assessment. Importantly, the use of non-invasive, blood-based biomarkers increases the practicality and accessibility of early detection methods, particularly in primary care and community settings where advanced neuroimaging or CSF testing may not be feasible. While this study was limited by its cross-sectional design, the implications are clear: integrating cognitive assessments with biomarker analysis offers a robust and scalable strategy for early diagnosis. Future longitudinal research should continue to explore these tools' prognostic value over time, ultimately informing clinical protocols and public health strategies for Alzheimer's prevention and care.

6. Recommendations

Based on the findings of this study, healthcare providers, policymakers, and researchers should consider integrating both cognitive screening tools and blood-based biomarkers into standard diagnostic pathways for Alzheimer's disease. Clinicians are encouraged to use the Montreal Cognitive Assessment (MoCA) alongside biomarker tests such as Aβ42/40 ratios and plasma p-tau181 to improve early diagnostic accuracy. Screening protocols should be established in primary care settings to identify at-risk individuals before clinical symptoms become severe. Additionally, training programs for healthcare personnel should include modules on interpreting biomarker data and administering cognitive assessments effectively. Governments and health systems should invest in making biomarker tests more affordable and widely available, particularly in under-resourced areas.

7. Practical Implications

This study offers several practical implications for clinical practice and public health policy. First, the high diagnostic accuracy of combined screening tools supports their immediate use in memory clinics and geriatric settings. Early detection through this combined approach can lead to earlier patient engagement in therapeutic interventions, lifestyle modifications, and long-term planning. It also enables caregivers to receive timely education and support. Furthermore, the scalability of blood-based biomarkers positions them as practical alternatives to more invasive and costly diagnostic methods such as cerebrospinal fluid analysis or PET imaging, facilitating broader screening efforts across diverse populations.

8. Future Research Directions

Future studies should adopt longitudinal designs to evaluate the predictive validity of these tools over time and their role in tracking disease progression. Expanding the sample size and including

more diverse populations in terms of ethnicity, education level, and comorbidities will enhance the generalizability of findings. Comparative studies examining the efficacy of additional biomarkers (e.g., plasma p-tau217, neurofilament light chain) are also recommended. Finally, research into cost-effectiveness, implementation barriers, and the development of automated screening platforms using artificial intelligence can further strengthen the practical utility of early detection models in real-world healthcare settings.

References

Ali, A. O. (2024). Unveiling Violence and Masculinity through a Psychoanalytic Study of Sam Shepard's *Curse of the Starving Class* (1977), Sarah Kane's *Blasted* (1995), and *The Body of a Woman as a Battlefield in Bosnian War* (1996) by Matei Visniec. *OTS Canadian Journal*, 3(9), 1–42. https://doi.org/10.58840/sjzgb278

Ali, A. O. (2024). Unveiling Violence and Masculinity through a Psychoanalytic Study of Sam Shepard's *Curse of the Starving Class* (1977), Sarah Kane's *Blasted* (1995), and *The Body of a Woman as a Battlefield in Bosnian War* (1996) by Matei Visniec. *OTS Canadian Journal*, 3(9), 1–42. https://doi.org/10.58840/sjzgb278

Ali, B. M. (2023). International Accounting Standards and Their Impact on the Banking Sector Performance. *OTS Canadian Journal*, 2(5). https://doi.org/10.58840/pdrw0345

Bayz, H. Q. (2024). The Role and Impact of the International Criminal Court in Global Justice. *OTS Canadian Journal*, 3(5). https://doi.org/10.58840/s5vqhh87

Blennow, K., Galasko, D., Perneczky, R., Quevenco, F. C., van der Flier, W. M., Akinwonmi, A., ... & Zetterberg, H. (2023). The potential clinical value of plasma biomarkers in Alzheimer's disease. *Alzheimer's & Dementia*, *19*(12), 5805-5816.

Fatah, S. H. (2025). Comparative Evaluation of Marginal Fit Between CAD/CAM and Conventional Metal-Ceramic Crowns. *OTS Canadian Journal*, 4(5), 91–100. https://doi.org/10.58840/b5gdcv24

Fatah, S. H. (2025). Comparative Evaluation of Marginal Fit Between CAD/CAM and Conventional Metal-Ceramic Crowns. *OTS Canadian Journal*, 4(5), 91–100. https://doi.org/10.58840/b5gdcv24

Fereshetian, S., Agranat, J. S., Siegel, N., Ness, S., Stein, T. D., & Subramanian, M. L. (2021). Protein and imaging biomarkers in the eye for early detection of Alzheimer's disease. *Journal of Alzheimer's Disease Reports*, *5*(1), 375-387.

Grande, G., Valletta, M., Rizzuto, D., Xia, X., Qiu, C., Orsini, N., ... & Vetrano, D. L. (2025). Blood-based biomarkers of Alzheimer's disease and incident dementia in the community. *Nature Medicine*, 1-9.

Hajjar, I., Okafor, M., Choi, J. D., Moore, E., Abrol, A., Calhoun, V. D., & Goldstein, F. C. (2023). Development of digital voice biomarkers and associations with cognition, cerebrospinal biomarkers, and neural representation in early Alzheimer's disease. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*, *15*(1), e12393.

Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., ... & Cummings, J. (2022). Designing the next-generation clinical care pathway for Alzheimer's disease. *Nature Aging*, *2*(8), 692-703.

Jiao, B., Li, R., Zhou, H., Qing, K., Liu, H., Pan, H., ... & Shen, L. (2023). Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer's disease using EEG technology. *Alzheimer's research & therapy*, *15*(1), 32.

Jiao, B., Ouyang, Z., Xiao, X., Zhang, C., Xu, T., Yang, Q., ... & Shen, L. (2025). Development and validation of machine learning models with blood-based digital biomarkers for Alzheimer's disease diagnosis: a multicohort diagnostic study. *EClinicalMedicine*, *81*.

Kareem, Z. (2023). What is Empiricism? Critically Evaluate its Value When Writing History. *OTS Canadian Journal*, 2(5). https://doi.org/10.58840/5t33ys67

Kareem, Z. (2023). What is Empiricism? Critically Evaluate its Value When Writing History. *OTS Canadian Journal*, 2(5). https://doi.org/10.58840/5t33ys67

Kerwin, D., Abdelnour, C., Caramelli, P., Ogunniyi, A., Shi, J., Zetterberg, H., & Traber, M. (2022). Alzheimer's disease diagnosis and management: perspectives from around the world. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*, *14*(1), e12334.

Langbaum, J. B., Zissimopoulos, J., Au, R., Bose, N., Edgar, C. J., Ehrenberg, E., ... & Aisen, P. S. (2023). Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials. *Alzheimer's & Dementia*, *19*(2), 696-707.

Lévesque, E. (2025). Exploring the Geographical Diversity of Canada: Landscapes, Climate, and Human Interaction. *OTS Canadian Journal*, 4(5), 82–90. https://doi.org/10.58840/cpyxa586

Lévesque, E. (2025). Exploring the Geographical Diversity of Canada: Landscapes, Climate, and Human Interaction. *OTS Canadian Journal*, 4(5), 82–90. https://doi.org/10.58840/cpyxa586

Papaliagkas, V., Kalinderi, K., Vareltzis, P., Moraitou, D., Papamitsou, T., & Chatzidimitriou, M. (2023). CSF biomarkers in the early diagnosis of mild cognitive impairment and Alzheimer's disease. *International Journal of Molecular Sciences*, *24*(10), 8976.

Pawlik, P., & Błochowiak, K. (2021). The role of salivary biomarkers in the early diagnosis of Alzheimer's disease and Parkinson's disease. *Diagnostics*, *11*(2), 371.

Qu, Y., Ma, Y. H., Huang, Y. Y., Ou, Y. N., Shen, X. N., Chen, S. D., ... & Yu, J. T. (2021). Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. *Neuroscience & Biobehavioral Reviews*, *128*, 479-486.

Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., ... & Alzheimer's Disease Neuroimaging Initiative. (2022). Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. *Alzheimer's & Dementia*, *18*(4), 824-857.

Vrahatis, A. G., Skolariki, K., Krokidis, M. G., Lazaros, K., Exarchos, T. P., & Vlamos, P. (2023). Revolutionizing the early detection of Alzheimer's disease through non-invasive biomarkers: the role of artificial intelligence and deep learning. *Sensors*, *23*(9), 4184.

Wei, W. (2025). Enhancing Quality of Care through Effective Gynecological Hospital Management: Strategies, Challenges, and Outcomes. *OTS Canadian Journal*, 4(5), 62–71. https://doi.org/10.58840/mc6crw68

Wei, W. (2025). Enhancing Quality of Care through Effective Gynecological Hospital Management: Strategies, Challenges, and Outcomes. *OTS Canadian Journal*, 4(5), 62–71. https://doi.org/10.58840/mc6crw68